Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): Pooled subset analyses from two randomized trials

1. Ramalingam, S.S.
2. O'Byrne, K.
3. Boyer, M.
4. Mok, T.
5. Jänne, P.A.
6. Zhang, H.
7. Liang, J.
8. Taylor, I.
9. Sbar, E.I.
10. Paz-Ares, L.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1093/ANNONC/MDV593 GOOGLE SCHOLAR lock_openOpen access editor

Data source: Scopus